Skip to main content
. Author manuscript; available in PMC: 2016 Jul 22.
Published in final edited form as: Clin Cancer Res. 2016 Jan 13;22(6):1313–1317. doi: 10.1158/1078-0432.CCR-15-1458

Table 1.

Anti-AXL agents currently in preclinical or clinical development

Company Compound Target(s) Indication Clinical status
Servier S49076 (kinase inhibitor) MET, AXL, FGFR1/2/3 Advanced solid tumors Phase I
2013-003079-37
Mirati Therapeutics Inc. MGCD516 (kinase inhibitor) MET, AXL, and members of the VEGFR, PDGFR, DDR2, TRK, and Eph families Advanced solid tumors Phase I
NCT02219711
Mirati Therapeutics Inc. MGCD265 (kinase inhibitor) MET/AXL Advanced malignancies Phase I
NTC00697632
Betta Pharmaceuticals Co., Ltd BPI-9016M (kinase inhibitor) MET/AXL Advanced solid tumors Phase I
NCT02478866
BerGenBio AS BGB324 (R428; kinase inhibitor) AXL NSCLC and AML Phase I/II
NCT02488408
NCT02424617
Tolero Pharmaceuticals and Astex Pharmaceuticals TP-0903 (kinase inhibitor) AXL Pancreatic cancer, lung cancer Preclinical

Abbreviations: AML, acute myelogenous leukemia; DDR, discoidin domain receptor; Eph, ephrin; FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor; TRK, tropomyosin receptor kinase.